Apixaban News and Research

RSS
Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

August edition of NPS RADAR includes reviews for new medicines listed on PBS

August edition of NPS RADAR includes reviews for new medicines listed on PBS

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Study: New genetic marker predicts warfarin dose in African-Americans

Study: New genetic marker predicts warfarin dose in African-Americans

New AAN guideline provides direction for use of blood thinners during surgery

New AAN guideline provides direction for use of blood thinners during surgery

Rivaroxaban ruled out for extended thromboprophylaxis

Rivaroxaban ruled out for extended thromboprophylaxis

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Oral Eliquis receives FDA approval for treatment of clots in non-valvular atrial fibrillation patients

Oral Eliquis receives FDA approval for treatment of clots in non-valvular atrial fibrillation patients

Studies examine current treatment standards for patients with clotting disorders

Studies examine current treatment standards for patients with clotting disorders

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Apixaban offers minor added benefit for adult patients after hip replacement

Apixaban offers minor added benefit for adult patients after hip replacement

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation